{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-086039","form_type":"8-K","ticker":"VKTX","cik":"0001607678","company_name":"Viking Therapeutics, Inc.","filed_at":"2024-07-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.755357+00:00","generated_at":"2026-05-31T17:00:47.019920+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Viking advances VK2735 to Phase 3 for obesity; Q2 net loss $22.3M","bullets":["VK2735 to advance to Phase 3 after positive VENTURE study; End-of-Phase 2 meeting with FDA planned for 2H24.","Oral VK2735 Phase 2 trial in obesity expected to start in 4Q24; 28-day weight loss up to 5.3% from baseline.","VK2809 met secondary endpoints in NASH/fibrosis; NASH resolution rates 63-75% vs 29% placebo; End-of-Phase 2 meeting 4Q24.","Q2 net loss $22.3M ($0.20/share) vs $19.2M ($0.19) year ago; R&D expenses rose to $23.8M.","Cash and investments $942M at June 30, 2024, up from $362M at year-end 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-086039","json":"https://secwatch.observer/filing/0000950170-24-086039.json","markdown":"https://secwatch.observer/filing/0000950170-24-086039.md","text":"https://secwatch.observer/filing/0000950170-24-086039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1607678/000095017024086039/0000950170-24-086039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1607678/000095017024086039/vktx-20240724.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T17:00:47.019920+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}